Zhongheng Group announced that its holding subsidiary Laimei Pharmaceutical and Tianzhihai Pharmaceutical signed a “Drug Marketing License Transfer Agreement” to transfer drug registration approval, commercial and marketing rights for vitamin D₂ softgels for 28 million yuan. The transaction does not constitute a related transaction or major asset restructuring. It does not require review by the board of directors or shareholders' meetings, but is subject to approval by the State Drug Administration. Transitional products are produced or relied on the original holder, which may result in untimely supply if there is a problem with the trustee. Furthermore, if the product is not selected for future procurement, price drops, or sales are poor, there is a risk of impairment of approved parts.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.